menu
    • menu

    Company profile for Bambusa Therapeutics

    NEW Drugs in Dev: 3
    ChemWerth works in generic API development & supply, non-infringement patent strategy development and regulatory support.

    Virtual Booth

    Contact Supplier

    AbbVie CDMO has been working with global companies to develop, manufacture & scale biopharmaceutical products.

    Virtual Booth

    Contact Supplier

    Lupin Manufacturing Solutions – delivering high-quality APIs & end-to-end CDMO services for faster, cost-effective drug development.

    Virtual Booth

    Contact Supplier

    Minakem delivers API, HPAPI, steroids & CDMO services for generics with FDA/GMP certification, regulatory know-how & proven success.

    Virtual Booth

    Contact Supplier

    LGM Pharma accelerates & optimizes the new product pathway from early development through commercialization.

    Virtual Booth

    Contact Supplier

    pharmacompass-2-m-2026-03-23

    Virtual Booth

    Contact Supplier

    EVENTS

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass

    Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

    Update your Virtual Booth on PharmaCompass, ask us

    About

    Bambusa Therapeutics, founded in 2024 by Dr. Shanshan Xu and Helmut Jeggle, is a biotechnology company based in Boston's Seaport district. We specialize in developing bispecific antibodies to treat immunological and inflammatory (I&I) disorders. Our mission is to advance immunology with innovative solutions, leveraging validated targets and antibody engineering to create best-in-disease therapies. In early 2025, we secured app...
    Bambusa Therapeutics, founded in 2024 by Dr. Shanshan Xu and Helmut Jeggle, is a biotechnology company based in Boston's Seaport district. We specialize in developing bispecific antibodies to treat immunological and inflammatory (I&I) disorders. Our mission is to advance immunology with innovative solutions, leveraging validated targets and antibody engineering to create best-in-disease therapies. In early 2025, we secured approximately $90 million in Series A financing, enabling us to progress our lead programs into Phase I clinical trials.

    List your booth number for exhibitions, ask us

    CONTACT DETAILS

    Click the arrow to open the dropdown
    Contact SupplierContact
    Google MapGoogle Map
    Full View ScreenFull View Screen
    Bambusa TherapeuticsUnited_States_of_America Flag
    Country
    Country
    U.S.A
    Address
    Address
    One Marina Park Drive Suite 1410 Boston, MA 02210
    Telephone
    Telephone
    Client Email
    Email
    enquiries@pharmacompass.com
    Client Website
    Website
    https://www.bambusatx.com/
    Linkedin
    Linkedin
    youtube
    YouTube
    Twitter
    Twitter

    Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

    Events

    Webinars & Exhibitions

    Request a meetingRequest a meeting
    Full Screen ViewFull Screen View
    Default Event

    IPhEB Russia

    Not Confirmed

    envelop Contact Supplier

    IPhEB Russia

    Post an Enquiry

    Meeting

    Digital content

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Bambusa Therapeutics Appoints Todd James Chief Financial Officer
    Bambusa Therapeutics Appoints Todd James Chief Financial Officer

    19 Mar 2026

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/bambusa-therapeutics-appoints-todd-james-chief-financial-officer-302718053.html

    PR NEWSWIRE
    19 Mar 2026
    Share Share
    Bambusa Therapeutics Launches Phase 1b COPD Trial for BBT002
    Bambusa Therapeutics Launches Phase 1b COPD Trial for BBT002

    06 Jan 2026

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/bambusa-therapeutics-announces-first-patient-dosed-in-phase-ib-proof-of-concept-copd-study-of-bbt002-reinforcing-bispecific-pipeline-momentum-302653951.html

    PR NEWSWIRE
    06 Jan 2026
    Share Share
    Bambusa Therapeutics Closes Series A-2 for Bispecific Platform
    Bambusa Therapeutics Closes Series A-2 for Bispecific Platform

    17 Nov 2025

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/bambusa-therapeutics-announces-completion-of-series-a-2-financing-to-accelerate-next-generation-bispecific-programs-302617188.html

    PR NEWSWIRE
    17 Nov 2025
    Share Share
    Bambusa Therapeutics Reports Strong Healthy Volunteer Results
    Bambusa Therapeutics Reports Strong Healthy Volunteer Results

    25 Sep 2025

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/bambusa-therapeutics-announces-highly-positive-healthy-volunteer-results-and-first-atopic-dermatitis-patient-dosed-in-phase-i-trial-of-bbt001-302567230.html

    PR NEWSWIRE
    25 Sep 2025
    Share Share
    Bambusa Therapeutics: First Subject Dosed in BBT002 Phase 1 Trial
    Bambusa Therapeutics: First Subject Dosed in BBT002 Phase 1 Trial

    30 May 2025

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/bambusa-therapeutics-announces-first-subject-dosed-in-phase-1-clinical-trial-of-bbt002-a-novel-platform-in-a-molecule-bispecific-antibody-for-broad-ii-conditions-and-us-fda-clearance-of-ind-application-for-bbt001-302469224.html

    PR NEWSWIRE
    30 May 2025
    Share Share
    I&I Startup Bambusa Nabs $90M for Bispecific Antibodies
    I&I Startup Bambusa Nabs $90M for Bispecific Antibodies

    14 Feb 2025

    // BIOSPACE

    https://www.biospace.com/business/i-i-startup-bambusa-nabs-90m-for-bispecific-antibodies

    BIOSPACE
    14 Feb 2025
    Share Share

    ABOUT THIS PAGE

    Ask Us for Pharmaceutical Supplier and Partner
    Ask Us, Find A Supplier / Partner
    No Commissions, No Strings Attached, Get Connected for FREE

    What are you looking for?

    How can we help you?

    The request can't be empty

    Please read our Privacy Policy carefully

    You must agree to the privacy policy

    The name can't be empty
    The company can't be empty.
    The email can't be empty Please enter a valid email.
    The mobile can't be empty
    • Privacy policy
    • Terms and conditions
    • Disclaimers
    • LinkedIn
    • Product listings are provided for informational purposes only. We do not supply or sell any products. Any products that may be covered by patent(s) are supplied solely for uses permitted under Section 107A of the Indian Patents Act and not for commercial sale.

    Market Place

    Market Place

    PharmaCompass

    Home

    Market Place

    Menu

    Post Enquiry

    Post Enquiry

    Market Place

    Market Place

    Search